ASTRO: Radiation oncologists urge Congress to advance bills that protect patient access to cancer care during the pandemic

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Radiation oncologists across the country met virtually with members of Congress this week to urge lawmakers to pass legislation that will safeguard access to high-quality, value-based health care for people with cancer.

The doctors met with congressional leaders and staff as part of the American Society for Radiation Oncology virtual Advocacy Day Nov. 19-20.

Radiation oncologists emphasized four legislative priorities in their meetings with lawmakers:

  • Prevent pending cuts to Medicare reimbursement for radiation therapy and provide temporary relief for physicians who continue to provide care during a pandemic.

  • Engage with the Centers for Medicare and Medicaid Services to fix the recently released Radiation Oncology Model and protect patient access to cancer care.

  • Reform a broken prior authorization system that, according to new data, has grown worse during the pandemic and unnecessarily delays patient access to lifesaving cancer treatments.

  • Increase investments in cancer research at the NIH and NCI.

Under the 2021 Medicare Physician Fee Schedule, CMS plans to move forward with changes to evaluation and management codes that will result in an overall reimbursement cut of 6% for radiation therapy services covered by Medicare. Many key services, including weekly management of patients currently undergoing treatment, will be cut by 10% or more.

“The proposed Medicare payment policy, set to start on Jan. 1, 2021, would cause significant additional financial challenges for radiation oncology practices as they enter the new year. Despite many practices already experiencing revenue declines of 20-30% due to the COVID-19 pandemic, CMS is still pushing ahead with large additional cuts for radiation oncology and other specialties,” Thomas J. Eichler, chair of the ASTRO board of directors, said in a statement.

ASTRO and a broad coalition of health care provider organizations are urging both Congress and CMS to waive or suspend the budget neutrality requirement, which would trigger the cuts. More than 200 bipartisan members of the House of Representatives also co-signed a letter last month urging Congress to pursue changes to the 2021 MPFS to avoid the excessively steep cuts.

Radiation oncologists are asking lawmakers to join the bipartisan cosponsors of the Holding Providers Harmless from Medicare Cuts During COVID-19 Act of 2020 (H.R. 8702), which would stabilize Medicare payment levels for the next two years and provide temporary relief from the threat of additional cuts for radiation oncology and other medical specialties.

Since CMS introduced the Radiation Oncology Model (RO Model) as a proposed advanced alternative payment model, ASTRO has said it expressed concerns with the model’s mandatory and excessive reimbursement cuts for radiation therapy providers.

While these concerns were echoed by bipartisan senators and representatives in oversight letters to CMS that requested changes to the model, they were not addressed in the agency’s final rule, ASTRO said.. Radiation oncologists are now asking Congress to intervene and protect patient access to radiation therapy treatments.

The RO Model in its current form would be a significant burden for the 950 practices required to participate, particularly as most are already experiencing revenue declines due to COVID-19, ASTRO said. ASTRO surveys of practices from the spring and summer of 2020 indicated that patient volume dropped at nearly 9 in 10 radiation oncology practices due to the pandemic, with an average decline of 31%. Half of the practices also had to reduce staff due to declining patient volume.

“The cuts to providers in the Radiation Oncology Model substantially exceed those in other models and, astoundingly, became more severe between the proposed and the final iterations from CMS,” said Eichler. “We are concerned that these mandatory cuts will financially jeopardize practices’ ability to deliver optimal care during the five-year demonstration period, especially as we continue to face a public health emergency. Unfortunately, CMS’ failure to listen to our recommendations has turned a model with great potential to improve patient care into one that we’re seriously worried will undermine patient care.”

ASTRO said radiation oncologists are asking specifically for the RO Model’s discount factors to be more consistent with other specialty models and more in line with the intent of value-based health care reform as outlined by the Medicare Access and CHIP Reauthorization Act of 2015.

Additionally, while an ASTRO-led effort recently secured a delay in the model’s start date from January 1 to July 1, 2021, physicians say that without significant changes, the delay only represents a stay of execution from the massive cuts. Reps. Brian Higgins (D-NY) and Rep. Mike Kelly (R-PA) are leading a joint letter to CMS asking for essential reforms to the RO Model before its implementation, ASTRO said.

While prior authorization was a major challenge for radiation oncology before the COVID-19 public health emergency, the burden has grown more difficult during the pandemic and physicians say they increasingly are constrained from exercising their clinical judgment in the best interest of their patients, according to ASTRO.

ASTRO is also asking lawmakers to join the bipartisan cosponsors of the Improving Seniors’ Timely Access to Care Act of 2019 (H.R. 3107), which would increase transparency in the prior authorization process and help curb delays for patients covered by Medicare Advantage plans.

ASTRO, in collaboration with cancer-focused organizations including ACS, is asking Congress to increase funding for cancer research at the NIH and NCI and provide emergency supplemental funding for projects that were stalled during the COVID-19 pandemic.

Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login